Evidence map›Paper›PMID 37087446›Full record

ArticleNature communications2023

Ethical considerations for researchers developing and testing minimal-risk devices.

Anna Wexler, Emily Largent

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anna WexlerDepartment of Medical Ethics & Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. awex@pennmedicine.upenn.edu.ORCID 0000-0002-6723-9038
Emily LargentDepartment of Medical Ethics & Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Funding

Technology Identification and Training CoreP30AG073105 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LARGENT, EMILY · 2021 to 2025
$21.2M
Adapting supported decision making to promote wellbeing and improve health outcomes for persons living with Alzheimer's disease and Alzheimer's disease related dementiasR01AG077111 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Emily Largent · 2022 to 2026
$3.1M
Do-it-Yourself and Direct-to-Consumer Medicine and Science: Assessing the Public Health Issues and Regulatory GapsDP5OD026420 · OD · UNIVERSITY OF PENNSYLVANIA · PI WEXLER, ANNA · 2018 to 2022
$2.0M
UNDERSTANDING HOW THE STUDY PARTNER REQUIREMENT IMPACTS THE DISCOVERY AND TRANSLATION OF PRECLINICAL ALZHEIMERS DISEASEK01AG064123 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LARGENT, EMILY · 2019 to 2023
$637k
NIA NIH HHS K01 AG064123NIA NIH HHS P30 AG073105NIA NIH HHS R01 AG077111NIH HHS DP5 OD026420
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ConfidentialityResearch PersonnelHumansRisk

Identifiers

PMID37087446
PMCPMC10122640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.